Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variantDai Chihara, Robert J. Kreitman, Lacey James-Echenique et al.|Blood Advances|2021Cited by 28
Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia VariantDai Chihara, Robert J. Kreitman, Evgeny Arons et al.|Blood|2019Cited by 3
Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemiaBrett Schroeder, Robert J. Kreitman, Constance M. Yuan et al.|Blood|2025Cited by 2
Effect of rituximab on remissions without minimal residual disease and immunogenicity in patients with relapsed/refractory hairy cell leukemia receiving moxetumomab pasudotox.Robert J. Kreitman, Ira Pastan, Constance M. Yuan et al.|Journal of Clinical Oncology|2024Cited by 1
Phase 1 trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox combined with rituximab for relapsed/refractory hairy cell leukemia.Robert J. Kreitman, Ira Pastan, Maryalice Stetler‐Stevenson et al.|Journal of Clinical Oncology|2021Cited by 0